No Prescription |
 |
 | ||
|
UROTONE Duvoid |
|
| ||
No Prescription » Prescription Drugs 16 » UROTONE Duvoid Bethanechol is used to relieve difficulties in urinating caused by surgery drugs or other factors.Bethanechol comes as a tablet to take by mouth. Bethanechol usually is taken two to four times a day. Follow the directions on your prescription label carefully and ask your doctor or pharmacist to explain any part you do not understand. Take bethanechol exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.Bethanechol usually is taken at evenly spaced intervals during the day.Take this medication on an empty stomach (at least 1 hour before or 2 hours after meals) to prevent stomach upset. Buy UROTONE Duvoid and other Prescription Drugs 16 products online at Medstore. 628
About UROTONE Duvoid: Product Type: Prescription Drugs 16 UROTONE ( Duvoid Myotonachol Urecholine Generic Bethanechol Chloride ) UROTONE (Duvoid Myotonachol Urecholine Generic Bethanechol Chloride) Duvoid Myotonachol Urecholine Generic Bethanechol Chloride 25mg Tabs 100 (10 x 10) Duvoid Myotonachol Urecholine Generic Bethanechol Chloride UROTONE
View more Prescription Drugs 16 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
